[{"NetIncomeLoss_1_Q2_USD":-12387000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":24336102.0,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2_Q2_USD":-1.08,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1_Q2_USD":-0.51,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":4256000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":177000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-103990000.0,"WeightedAverageNumberOfSharesIssuedBasic_2_Q2_shares":23788944.0,"WeightedAverageNumberOfSharesIssuedBasic_1_Q2_shares":24376891.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":23743058.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":1000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":1598784.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":453000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":2035000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":130704000.0,"Assets_0_Q2_USD":139676000.0,"ShareBasedCompensation_2_Q2_USD":4123000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q2_shares":3374819.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":69842000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":2212000.0,"AssetsCurrent_0_Q2_USD":136077000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1277000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":2802000.0,"DepreciationAndAmortization_2_Q2_USD":595000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":10986000.0,"ProceedsFromStockPlans_2_Q2_USD":411000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":504000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":267000.0,"IncreaseDecreaseInDeferredRevenue_2_Q2_USD":3788000.0,"CommonStockValue_0_Q2_USD":2000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":1811000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":-5000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":70736000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":6091000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":8000000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-25369000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-12217000.0,"OtherAssetsNoncurrent_0_Q2_USD":389000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":28957000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":309908000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":152000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":369000.0,"MarketableSecuritiesCurrent_0_Q2_USD":103993000.0,"DepreciationAndAmortization_1_Q2_USD":400000.0,"DeferredRevenueNoncurrent_0_Q2_USD":1775000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":21669000.0,"WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_2_Q2_shares":45886.0,"OperatingIncomeLoss_2_Q2_USD":-25548000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-12120000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":5000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-199000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-15172000.0,"WorkersCompensationLiabilityCurrent_0_Q2_USD":2139000.0,"LiabilitiesCurrent_0_Q2_USD":13080000.0,"DeferredRevenueCurrent_0_Q2_USD":6013000.0,"AccountsPayableCurrent_0_Q2_USD":2381000.0,"NonoperatingIncomeExpense_2_Q2_USD":526000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-25022000.0,"NonoperatingIncomeExpense_1_Q2_USD":391000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":483000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":164000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":28957000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":411000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":0.0,"DividendsCommonStock_2_Q2_USD":0.0,"ProceedsFromIssuanceOfConvertiblePreferredStock_2_Q2_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":3210000.0,"NetIncomeLoss_2_Q2_USD":-25526000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":3127000.0,"WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_1_Q2_shares":40789.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":153000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":111892000.0,"OperatingIncomeLoss_1_Q2_USD":-12511000.0,"InvestmentIncomeAmortizationOfPremium_2_Q2_USD":51000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":139676000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":4123000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":2035000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":9813000.0,"OperatingExpenses_2_Q2_USD":27760000.0,"OperatingExpenses_1_Q2_USD":13788000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":6603000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.08,"ProfitLoss_2_Q2_USD":-25526000.0,"OtherLiabilitiesCurrent_0_Q2_USD":430000.0,"StockholdersEquity_0_Q2_USD":122611000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":98000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":130552000.0,"DeferredRentCreditNoncurrent_0_Q2_USD":2210000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-187476000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-48426000.0,"CommonStockSharesOutstanding_0_Q2_shares":24442842.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.51,"AccruedProfessionalFeesCurrent_0_Q2_USD":149000.0,"Ticker":"RAPT","CIK":"1673772","name":"RAPT THERAPEUTICS, INC.","OfficialName":"RAPT Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"595076458.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200813"}]